Prot # GS-US 342-1140: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Inf

Project: Research project

Project Details

Effective start/end date6/26/146/26/17


  • PRA Health Sciences (GS-US 342-1140)
  • Gilead Sciences, Inc. (GS-US 342-1140)